Scarica l'app Stockscreener
10.77
2.31%
-0.26
Dopo l'orario di chiusura:
10.42
-0.35
-3.25%
Precedente Chiudi:
$11.03
Aprire:
$11.09
Volume 24 ore:
374.75K
Relative Volume:
0.44
Capitalizzazione di mercato:
$570.37M
Reddito:
$1.02B
Utile/perdita netta:
$-757.20M
Rapporto P/E:
-0.7297
EPS:
-14.76
Flusso di cassa netto:
$-257.90M
1 W Prestazione:
+2.23%
1M Prestazione:
-13.03%
6M Prestazione:
+20.93%
1 anno Prestazione:
+13.78%
Intervallo 1D:
$10.67
$11.12
Intervallo di 1 settimana:
$10.40
$11.45
Portata 52W:
$4.02
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
Nome
Emergent Biosolutions Inc
Settore
Telefono
240-631-3200
Indirizzo
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
10.86 | 579.30M | 1.02B | -757.20M | -257.90M | -14.76 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.38 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.63 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.92 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
476.07 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2024-03-07 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-08-29 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Iniziato | The Benchmark Company | Buy |
| 2021-02-24 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-07-31 | Reiterato | Chardan Capital Markets | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-09-04 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-08-03 | Reiterato | Chardan Capital Markets | Buy |
| 2018-06-13 | Iniziato | Argus | Buy |
| 2018-04-25 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2018-01-16 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | Singular Research | Buy |
| 2016-04-15 | Iniziato | Chardan Capital Markets | Buy |
| 2016-03-28 | Iniziato | Singular Research | Buy |
| 2016-02-19 | Iniziato | Wells Fargo | Outperform |
| 2014-05-15 | Iniziato | Summer Street Research | Buy |
| 2011-05-31 | Reiterato | WBB Securities | Strong Buy |
| 2011-01-10 | Reiterato | Wedbush | Outperform |
| 2010-11-05 | Reiterato | Wedbush | Outperform |
| 2010-08-18 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Reiterato | Caris & Company | Buy |
Mostra tutto
Emergent Biosolutions Inc Borsa (EBS) Ultime notizie
Emergent BioSolutions Inc. to Host Conference Call on Q4 and Full Year 2025 Financial Results - Quiver Quantitative
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - The Manila Times
Emergent Biosolutions Inc. $EBS Shares Purchased by Allianz Asset Management GmbH - MarketBeat
How strong dollar benefits Emergent BioSolutions Inc. stockJuly 2025 Snapshot & Capital Efficient Trade Techniques - mfd.ru
New York State Common Retirement Fund Has $4.60 Million Stock Holdings in Emergent Biosolutions Inc. $EBS - MarketBeat
How Emergent Biosolutions Inc. (EBS) Affects Rotational Strategy Timing - Stock Traders Daily
NYAG's Insider Trading Case A Power Grab, Judge Told - Law360
Retail Surge: Can Emergent BioSolutions Inc stock outperform in a bear marketPortfolio Value Summary & Free Community Consensus Stock Picks - baoquankhu1.vn
Federated Hermes Inc. Raises Position in Emergent Biosolutions Inc. $EBS - MarketBeat
Emergent BioSolutions Inc. (EBS) Stock Analysis: Evaluating a 13.45% Upside Potential Amidst Sector Challenges - DirectorsTalk Interviews
Emergent Biosolutions (NYSE:EBS) Share Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
Why is Emergent BioSolutions Inc stock going downJuly 2025 Market Mood & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Market Review: Is Emergent BioSolutions Inc stock showing strong momentumWeekly Stock Analysis & Daily Entry Point Alerts - baoquankhu1.vn
Lipid Nanoparticle Manufacturing Market: An 18.9% CAGR Market Driven by Nucleic Acid Therapies - GlobeNewswire Inc.
Emergent BioSolutions Inc. (EBS) Stock Analysis: Is The 11.66% Upside Worth The Risk? - DirectorsTalk Interviews
Emergent Biosolutions (NYSE:EBS) Share Price Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Biotech Co. Gets OK For $10M Stalking Horse Bid - Law360
Emergent BioSolutions (EBS) receives a new order from US Department of War - MSN
Bispecific Antibody Market with Insights from Immunomedics, - openPR.com
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing - FinancialContent
Former biotech CEO sued over COVID vaccine alleged insider trading - AOL.com
Moving Averages: Will Norfolk Southern Corporation outperform tech stocksJuly 2025 Catalysts & Safe Entry Trade Signal Reports - baoquankhu1.vn
Ex-Biotech CEO Cashed In $10M Ahead Of COVID Vaccine Crisis: Lawsuit - AOL.com
JPM movers: ImmunityBio rises to the top - BioCentury
FRAUD AND MANIPULATION—N.Y. Sup.: New York’s AG sues former Emergent BioSolutions CEO for insider trading - VitalLaw.com
Insider Sell: Can BOS Better Online Solutions Ltd disrupt its industryPortfolio Value Summary & AI Driven Price Forecasts - baoquankhu1.vn
Retail Trends: Is CMREPRC stock technically oversoldEarnings Trend Report & Daily Price Action Insights - baoquankhu1.vn
Lobbying Update: $430,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Quiver Quantitative
New York Sues Former C.E.O. of Covid Vaccine Maker Over Insider Trading - The New York Times
Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading - BioPharma Dive
Emergent BioSolutions (EBS) Receives a New Order from US Department of War - Insider Monkey
Emergent BioSolutions (EBS) Sued for Insider Trading, Agrees to $900K Settlement - Intellectia AI
Read This Before Judging Emergent BioSolutions Inc.'s (NYSE:EBS) ROE - Yahoo Finance
Emergent BioSolutions Inc. (EBS) Stock Analysis: Exploring a 23% Upside Potential and Robust Free Cash Flow - DirectorsTalk Interviews
Ex-CEO sued by New York for insider trading tied to COVID-19 vaccine contamination - whtc.com
New Packaging Option for Narcan Nasal Spray Aims to Reduce Stigma - Psychiatry Advisor
Ex-CEO Of COVID Vax Maker Accused Of Insider Trading - Law360
Emergent Biosolutions Stock Plummets Amid Insider Trading Allegations Against Former CEO - Stocktwits
NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading - The Wall Street Journal
Ex-CEO sued by New York for insider trading tied to COVID vaccine contamination - Reuters
NY Sues Ex-Emergent BioSolutions CEO for Insider Trading (1) - Bloomberg Law News
Emergent Biosolutions (NYSE:EBS) Stock Price Down 7.4%What's Next? - MarketBeat
N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading -- Update - marketscreener.com
N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading - marketscreener.com
AstraZeneca (AZN) Involvement in Emergent's Legal Settlement - GuruFocus
Investors five-year losses continue as Emergent BioSolutions (NYSE:EBS) dips a further 7.5% this week, earnings continue to decline - Sahm
Emergent BioSolutions makes $100 million voluntary loan prepayment By Investing.com - Investing.com Nigeria
Emergent Biosolutions' Former CEO Sued for Insider Trading, Facing $900,000 Penalty - Intellectia AI
Emergent BioSolutions Inc CEO Presents at J.P. Morgan Healthcare Conference - TradingView
Does Emergent BioSolutions (NYSE:EBS) Have A Healthy Balance Sheet? - 富途牛牛
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness - The Manila Times
Emergent Biosolutions Inc Azioni (EBS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
10.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):